It has a retinoid and salicylic acid
Novo Nordisk holds semaglutide composition-of-matter and formulation patents expiring between 2031 and 2038 across different jurisdictions, with FlexTouch autoinjector device patents extending GLP-1 competitive protection in the U.S
46 showed that a preserved responsiveness to the endothelium-dependent vasodilator acetylcholine, administered intracoronarily, is associated with a significantly lower incidence of cardiovascular events defined as a composite end point, including cardiovascular death, unstable angina, myocardial infarction, coronary revascularization, ischemic stroke and peripheral artery revascularization
After taking these results to my physician, she suggested I try a low-dose GLP-1 as part of a broader strategy that also included strength training, increasing my protein intake, improving sleep, following a personalized nutrition plan, and taking targeted supplements